Novel therapeutics for patients with non-muscle-invasive bladder cancer

References

• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49(3), 466–465 (2006).
   PubMed Web of Science ®Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics21(18), 1315–1330 (2003).
   PubMed Web of Science ®Google Scholar
• Brassell SA, Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J. Natl Compr. Canc. Netw.4(10), 1027–1036 (2006).
   PubMedGoogle Scholar
• Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumors. Urol. Clin. North Am.18(3), 525–528 (1991).
   PubMedGoogle Scholar
• Melekos MD, Chionis H, Pantazakos A et al. Intravesical bacillus Calmette–Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J. Urol.149(4), 744–748 (1993).
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P, Milani C et al. A low dose bacillus Calmette–Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol.146(1), 32–35 (1991).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168(5), 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol.54(2), 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171(6 Pt 1), 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol.156(6), 1934–1940 (1996).
   PubMed Web of Science ®Google Scholar
• Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res.21(1B), 765–769 (2001).
   PubMed Web of Science ®Google Scholar
• Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol. Clin. North Am.27(1), 125–135 (2000).
   PubMed Web of Science ®Google Scholar
• Campodonico F, Mattioli F, Manfredi V et al. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. Anticancer Res.27(2), 1179–1183 (2007).
   PubMedGoogle Scholar
• Dalbagni G, Russo P, Bochner B et al. Phase II trial of intravesical gemcitabine in bacille Calmette–Guerin-refractory transitional cell carcinoma of the bladder. J. Clin. Oncol.24(18), 2729–2734 (2006).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette–Guerin-refractory transitional-cell carcinoma of the bladder. J. Clin. Oncol.20(15), 3193–3198 (2002).
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Masson P, Murphy AM et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol.24(19), 3075–3080 (2006).
   PubMed Web of Science ®Google Scholar
• Witjes JA, van der Heijden AG, Vriesema JL et al. Intravesical gemcitabine: a Phase 1 and pharmacokinetic study. Eur. Urol.45(2), 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Witjes JA, Kolli PS. Apaziquone for non-muscle invasive bladder cancer: a critical review. Expert Opin. Investig. Drugs17(7), 1085–1096 (2008).
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Moonen PM, Cornel EB et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J. Urol.176(4 Pt 1), 1349–1353 (2006).
   PubMed Web of Science ®Google Scholar
• Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell10(4), 947–959 (1999).
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Gacci M et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology66(4), 726–731 (2005).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Vespasiani G, Giannantoni A et al. Electromotive delivery of mitomycin C into human bladder wall. Cancer Res.57(5), 875–880 (1997).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol.170(3), 777–782 (2003).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol.7(1), 43–51 (2006).
   PubMed Web of Science ®Google Scholar
• Bochner BH. Intravesical bacillus Calmette–Guerin combined with electromotive mitomycin for high-risk superficial bladder cancer. Nat. Clin. Pract. Oncol.3(9), 474–475 (2006).
   PubMedGoogle Scholar
• Colombo R, Lev A, Da Pozzo LF et al. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J. Urol.153(3 Pt 2), 959–963 (1995).
   PubMed Web of Science ®Google Scholar
• Herman TS, Teicher BA, Jochelson M et al. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int. J. Hyperthermia4(2), 143–158 (1988).
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol.21(23), 4270–4276 (2003).
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur. Urol.46(1), 65–71 (2004).
   PubMed Web of Science ®Google Scholar
• Bochner BH. Gene therapy in bladder cancer. Curr. Opin. Urol.18(5), 519–523 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher M, Benedict WF, Culter DL et al. Preliminary results of a Phase I study with intravesical administration of adenoviral-mediated interferon-α for patients with BCG refractory transitional cell carcinoma of the bladder. Presented at: American Urological Association Meeting. IL, USA, 25–30 April 2009.
   Google Scholar
• Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette–Guerin treatment for superficial bladder cancer. J. Urol.167(1), 364–367 (2002).
   PubMed Web of Science ®Google Scholar
• Sidi AA, Ohana P, Benjamin S et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette–Guerin. J. Urol.180(6), 2379–2383 (2008).
   PubMed Web of Science ®Google Scholar
• Berger AP, Steiner H, Stenzl A et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology61(2), 338–341 (2003).
   PubMed Web of Science ®Google Scholar
• Waidelich R, Beyer W, Knuchel R et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology61(2), 332–337 (2003).
   PubMed Web of Science ®Google Scholar
• Shackley DC, Briggs C, Gilhooley A et al. Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int.89(7), 665–670 (2002).
   PubMedGoogle Scholar
• Oosterlinck W, Lobel B, Jakse G et al. Guidelines on bladder cancer. Eur. Urol.41(2), 105–112 (2002).
   PubMed Web of Science ®Google Scholar